Nemes Rush Group’s SELLAS Life Sciences SLS Stock Holding History

Nemes Rush Group’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$123K	Hold	10,000	–	–	0.01%	253
2026 Q2	$148K	Hold	10,000	–	–	0.01%	248
2026 Q1	$42.3K	Hold	10,000	–	–	﹤0.01%	381
2025 Q4	$37.7K	Hold	10,000	–	–	﹤0.01%	377
2025 Q3	$16.1K	Hold	10,000	–	–	﹤0.01%	442
2025 Q2	$21.9K	Hold	10,000	–	–	﹤0.01%	411
2025 Q1	$10.8K	Hold	10,000	–	–	﹤0.01%	459
2024 Q4	$10.4K	Hold	10,000	–	–	﹤0.01%	460
2024 Q3	$10.1K	Hold	10,000	–	–	﹤0.01%	400
2024 Q2	$11.9K	Hold	10,000	–	–	﹤0.01%	392
2024 Q1	$10.1K	Hold	10,000	–	–	﹤0.01%	435
2023 Q4	$10.6K	Hold	10,000	–	–	﹤0.01%	421
2023 Q3	$16.4K	Hold	10,000	–	–	﹤0.01%	356
2023 Q2	$15.7K	Buy	+10,000	New	+$16.1K	﹤0.01%	382

Other funds holding SLS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

DAGCO Inc Westlake, Ohio $576M AUM 21.79% 1-Year Est. Return

Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Opus Capital Group Cincinnati, Ohio $1.02B AUM 13.75% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Nemes Rush Group's SLS Position: Q3 2026 in Review

Nemes Rush Group held its SELLAS Life Sciences (SLS) position steady in Q3 2026 at 10,000 shares worth $123K. The position accounts for 0.01% of the portfolio, ranked #253.

Nemes Rush Group first reported a position in SLS in Q2 2023 and has held it in 14 quarters since. The position peaked at $148K in Q2 2026. 112 funds tracked by Wall St. Rank hold SLS as of Q3 2026.

Nemes Rush Group held 10,000 shares of SELLAS Life Sciences worth $123K as of Q3 2026.
Nemes Rush Group left its SELLAS Life Sciences share count unchanged in Q3 2026.
SELLAS Life Sciences made up 0.01% of Nemes Rush Group's portfolio in Q3 2026, its #253 holding.
Nemes Rush Group first reported a position in SELLAS Life Sciences in Q2 2023 and has held it in 14 quarters since.
Nemes Rush Group's SELLAS Life Sciences position peaked at $148K in Q2 2026.
112 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.